跳至主要内容
临床试验/NCT00507286
NCT00507286Unknown不适用

Efficacy and Safety Study of Using Oral Sildenafil and Intracavernosal Alprostadil Injection as a Combined Pharmacotherapy for Men With Difficult to Treat Erectile Dysfunction.

Keogh Institute for Medical Research2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2007年5月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
入组人数
20
试验地点
2
主要终点
Sexual Encounter Profile SEP2 and SEP3

研究概览

简要总结

Erectile dysfunction (ED or impotence) is a common medical condition affecting many men world wide. The most commonly used treatment for ED are oral medications like Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil). If these are not effective the use of an injection into the penis (intracavernosal injection or ICI) is necessary. However in some men neither of these therapies is successful.

Hypothesis: An adequate erection may be achieved in men with difficult-to-treat erectile dysfunction, when they are treated with a therapy of combination of tablet and penile injection, when a single treatment therapy has failed for these men.

Aim of the study is to test the safety and efficacy of a combination of Viagra and Caverjet Impulse in a group of men who had failed to achieve an adequate response to the maximum recommended dose of either Viagra, Cialis or Levitra and Caverjet Impulse, when these treatments were used alone.

20 men with difficult to treat ED will be given oral medication, intracavernosal therapy or the combination in a single-blind randomised study.

Informed consent will be signed prior to any study procedures being carried out. All participants are 'blinded' to their study treatments. Participants who have satisfactory response to any of the tablets or penile injections, will be excluded from the study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men aged 20 years and over
  • History of ED for at least 6 months
  • IIEF score <26
  • Failure to achieve an adequate response to the maximum recommended therapeutic dose of an approved ED treatments, when either of these treatments was used alone.

排除标准

  • Concurrent treatment with nitrate-containing medications
  • Significant cardiac, hepatic, renal or respiratory dysfunction
  • Systolic blood pressure of less than 100mm Hg
  • Myocardial infarction, serious cardiac arrhythmia, cardiac surgery, or stroke within the last 6 months
  • Significant penile fibrosis, curvature or infection
  • Reported significant side effects of using PDE5 inhibitors or alprostadil
  • Hypersensitivity to PDE5 inhibitors or alprostadil

结局指标

主要结局

Sexual Encounter Profile SEP2 and SEP3

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验